Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment?
about
Chimeric Glutathione S-Transferases Containing Inserts of Kininogen Peptides: POTENTIAL NOVEL PROTEIN THERAPEUTICSThe Fibrin Matrix Regulates Angiogenic Responses within the Hemostatic Microenvironment through Biochemical ControlNeuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release.The role of platelets in tumour growth.Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released.Heparin impairs angiogenesis through inhibition of microRNA-10b.Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma.Protease-activated receptors in cancer: A systematic review.Angiogenesis inhibitors found within the haemostasis pathway.A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy.Paradox of simultaneous intestinal ischaemia and hyperaemia in inflammatory bowel disease.Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse modelA platelet-mimetic paradigm for metastasis-targeted nanomedicine platformsFrom nutraceuticals to pharmaceuticals to nanopharmaceuticals: a case study in angiogenesis modulation during oxidative stress.Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation.Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.The platelet contribution to cancer progression.Mechanisms of resistance to vascular endothelial growth factor blockade.A review of ELTD1, a pro-angiogenic adhesion GPCR.Targeted prodrug approaches for hormone refractory prostate cancer.Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis.Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis.The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients.Correlation of percentage changes in platelet counts with recurrence rate following radical nephrectomy.Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrixA novel fragment derived from the beta chain of human fibrinogen, beta43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo.Platelet-released supernatant increases matrix metalloproteinase-2 production, migration, proliferation, and tube formation of human umbilical vascular endothelial cells.Proteomic identification of serum biomarkers for head and neck cancer surveillance.Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer
P2860
Q27679018-B8BE6D57-182C-432C-890B-AEBC207C118CQ28547610-89E577BE-0CAD-4F1E-B9E8-099087C21FF8Q33525290-BC0FCAAF-A8A2-4B06-9828-744B675F8E36Q33803558-63AA8E64-2736-4097-9EC5-A1E0A8C4E3FAQ34584213-65E34EE5-047A-4073-AE91-8CCA6222DE73Q35128227-F01F0E91-F204-4CE8-AC74-DC67DFC1802DQ35879110-74D65A3E-5FBE-4A25-8667-1357D754059CQ36121203-93140FFC-8586-4601-9F30-8F27F2A9D60AQ36166483-DB309031-CCC6-4279-AEDA-28BBF22A39C4Q36263207-D6B74BB7-F30E-4F13-AB2F-A3B29F282FCEQ36264902-29A99736-706C-4E88-AB0F-8E2AB120FFFFQ36308321-D5C5376D-662A-4C5E-99D5-3AFB7C1DDA21Q36949458-868200F1-878C-4521-8612-C5E7B7A588B9Q36959674-7CDE9861-BD47-4682-8F43-CB253565A4E1Q36979002-AC6A42AC-8362-4952-B2F0-307C587EA26AQ37482521-200F3177-75EF-4087-B98F-F6B74B055AB0Q37805788-77F20BF0-3549-4C05-9DA5-50AC897FF233Q37956587-14CD7902-B222-4F5B-A367-A1A60296EE36Q38268465-56A8ED5D-761D-4E1F-BE0B-9556D145E996Q38295983-7134ADBD-A318-40C5-9C6D-A8ACA44A10FCQ38964255-269C4D56-313B-420D-BFBD-EABED21C544EQ39368829-E4F19D4A-A33A-4B19-B1C7-63AC591485F1Q40281259-D748A2F0-F1E8-407C-8632-F4C4378A4276Q41727394-F8AC4A87-4486-4DF5-9438-8DD2B04559B3Q42427374-B691BAE4-1C7B-4F0F-940B-942284BB9D0FQ42567361-B54AAA17-E335-4A9B-8C2F-C501A498CA52Q42914728-677108E8-07A3-432B-8D09-C05B9317AE5EQ45130858-314C998E-BF7C-4503-9581-ED9895F4E4DFQ46010717-87F50974-686B-43A2-9F84-EFDD2DD31B9DQ58003008-7CDF3456-A3BC-47AD-A04D-D684C07903E0
P2860
Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Hemostatic regulators of tumor ...... c agents for cancer treatment?
@ast
Hemostatic regulators of tumor ...... c agents for cancer treatment?
@en
type
label
Hemostatic regulators of tumor ...... c agents for cancer treatment?
@ast
Hemostatic regulators of tumor ...... c agents for cancer treatment?
@en
prefLabel
Hemostatic regulators of tumor ...... c agents for cancer treatment?
@ast
Hemostatic regulators of tumor ...... c agents for cancer treatment?
@en
P2093
P356
P1476
Hemostatic regulators of tumor ...... c agents for cancer treatment?
@en
P2093
Andreas Makris
Claire E Lewis
Malcolm Reed
Martina E Daly
P304
P356
10.1093/JNCI/DJG101
P407
P577
2003-11-01T00:00:00Z